PURPOSE: To evaluate the feasibility and efficacy of sorafenib and everolimus in renal cell carcinoma (RCC). METHODS: Patients with advanced RCC and ≤ 1 previous targeted therapy were treated. RESULTS: Maximum tolerated doses were sorafenib 200 mg PO BID, everolimus 35 mg PO once weekly. Dose-limiting toxicity was hand-foot syndrome. The response rate was 13%; median PFS was 5.45 months (95% CI: 3.8-7.6). Skin toxicity, fatigue, hypertension, proteinuria, and mucositis (usually Grade 2) were common. CONCLUSIONS: Fifty percent doses of sorafenib and everolimus were required when these drugs were combined. No increase in efficacy was suggested; toxicity was modestly increased.
PURPOSE: To evaluate the feasibility and efficacy of sorafenib and everolimus in renal cell carcinoma (RCC). METHODS:Patients with advanced RCC and ≤ 1 previous targeted therapy were treated. RESULTS: Maximum tolerated doses were sorafenib 200 mg PO BID, everolimus 35 mg PO once weekly. Dose-limiting toxicity was hand-foot syndrome. The response rate was 13%; median PFS was 5.45 months (95% CI: 3.8-7.6). Skin toxicity, fatigue, hypertension, proteinuria, and mucositis (usually Grade 2) were common. CONCLUSIONS: Fifty percent doses of sorafenib and everolimus were required when these drugs were combined. No increase in efficacy was suggested; toxicity was modestly increased.
Authors: Sumanta K Pal; Miaoling He; Tommy Tong; Huiqing Wu; Xueli Liu; Clayton Lau; Jin-Hui Wang; Charles Warden; Xiwei Wu; Sabina Signoretti; Toni K Choueiri; Jose A Karam; Jeremy O Jones Journal: Mol Cancer Res Date: 2014-09-02 Impact factor: 5.852
Authors: Giuseppe Tarantino; Paolo Magistri; Roberto Ballarin; Raffaele Di Francia; Massimiliano Berretta; Fabrizio Di Benedetto Journal: Front Pharmacol Date: 2016-10-21 Impact factor: 5.810
Authors: Lucia Nogova; Christian Mattonet; Matthias Scheffler; Max Taubert; Masyar Gardizi; Martin L Sos; Sebastian Michels; Rieke N Fischer; Meike Limburg; Diana S Y Abdulla; Thorsten Persigehl; Carsten Kobe; Sabine Merkelbach-Bruse; Jeremy Franklin; Heiko Backes; Roland Schnell; Dirk Behringer; Britta Kaminsky; Martina Eichstaedt; Christoph Stelzer; Martina Kinzig; Fritz Sörgel; Yingying Tian; Lisa Junge; Ahmed A Suleiman; Sebastian Frechen; Dennis Rokitta; Dongsheng Ouyang; Uwe Fuhr; Reinhard Buettner; Jürgen Wolf Journal: Cancer Med Date: 2020-05-21 Impact factor: 4.452
Authors: Claudia Arena; Giuseppe Troiano; Alfredo De Lillo; Nunzio F Testa; Lorenzo Lo Muzio Journal: Biomed Res Int Date: 2018-05-24 Impact factor: 3.411